6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection
Status:
Completed
Trial end date:
2016-11-30
Target enrollment:
Participant gender:
Summary
Part A Primary Objective To determine the safety of six months of PRTX-100 administration.
Part B Primary Objective To obtain antisera from normal volunteers that have developed
anti-PRTX-100 antibodies.
Secondary Objective(s) To assess rheumatoid arthritis activity during the period of PRTX-100
treatment To evaluate the development of anti-PRTX-100 antibodies To explore feasibility of
joint evaluations with ultrasound To explore feasibility of biomarkers as disease markers